Drugs / 11C-PS13
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07856043 | Oct 2026 → Jun 2028 expected | cerebrovascular disorder, cognitive impairment with or without cerebellar ataxia, symptomatic heart failure | Stony Brook University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06920628 | Jun 2025 → Feb 2028 expected | long COVID-19 | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 1 | NCT04582916 | Jul 2021 → Oct 2029 expected | depressive disorder | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05062083 | Jun 2022 → Sep 2023 | multiple sclerosis | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[11C\]PS13 | “To see if a radioactive tracer (\[11C\]PS13) can highlight brain inflammation in those who had COVID-19 but still have symptoms that affect the brain.” NCT06920628 ↗ |
| Known as | [carbon-11]PS13 | “[11C]PS13: [carbon-11]PS13; COX-1 PET radioligand” NCT07856043 ↗ |
| Modality | Diagnostic / imaging agent | “radioactive tracer” NCT06920628 ↗ |
| Route | Intravenous | “Injected IV followed by PET scanning” NCT04582916 ↗ |